NASDAQ$ADPT
Adaptive Biotechnologies Corporation · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported strong growth with continued momentum across research, diagnostic and drug discovery.
Adaptive Biotechnologies reported a revenue of $39.5 million for Q3 2021, a 50% increase compared to Q3 2020. The company's net loss was $56.0 million, compared to $36.7 million for the same period in 2020.
- Revenue of $39.5 million for the third quarter 2021, representing a 50% increase from the third quarter 2020
- clonoSEQ clinical sequencing volume in the third quarter 2021 grew 47% versus prior year and 8% over the second quarter of 2021
- Launched an enhanced version of the clonoSEQ Assay for CLL patients, which provides IGHV mutation status in the same test where we measure the trackable MRD sequence
- Received positive Tech Assessment from MolDX for coverage of T-Detect COVID in certain cases including immunocompromised patients
Headline financials
Revenue & EPS history
Adaptive Biotechnologies · Revenue · Quarterly
$39.5M
Revenue by segment
Adaptive Biotechnologies · $58.9M total across 2 segments · Q2 2025
- MRD$49.9M—84.8%
- Immune Medicine$8.94M—15.2%
Forward guidance
Adaptive Biotechnologies reiterates full year 2021 revenue to be in the range of $148 million to $155 million, representing 54% growth at the mid-point of the range over full year 2020 revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
+1.3%
Avg return
Earnings day
+0.0%
Avg return
5 days after
-0.9%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+33.2%
Q1 2025
Best reaction
-22.2%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +1.2% | -1.9% | +22.6% | |
| Q4 2025 | -4.3% | -5.2% | -9.8% | |
| Q3 2025 | -4.8% | -6.8% | -5.2% | |
| Q1 2025 | +33.2% | +19.7% | +29.3% | |
| Q4 2024 | -3.2% | +6.8% | -6.7% | |
| Q3 2024 | +1.2% | +3.1% | +9.0% | |
| Q2 2024 | -5.5% | +1.3% | +3.3% | |
| Q1 2024 | -1.2% | +8.7% | +21.1% | |
| Q4 2023 | +9.4% | +6.4% | -10.5% | |
| Q3 2023 | -22.2% | -9.3% | +4.4% | |
| Q2 2023 | -15.5% | -18.8% | -17.5% | |
| Q1 2023 | -8.3% | -5.8% | +6.4% | |
| Q4 2022 | +15.4% | +9.3% | -3.3% | |
| Q3 2022 | +13.2% | -0.9% | +14.1% | |
| Q2 2022 | +19.3% | +22.8% | -8.4% | |
| Q1 2022 | -1.1% | -19.2% | -22.5% | |
| Q4 2021 | +5.3% | -8.0% | -15.3% | |
| Q3 2021 | +6.7% | +5.7% | -26.6% | |
| Q2 2021 | +4.8% | -2.4% | +9.8% | |
| Q1 2021 | +0.9% | -11.2% | -1.0% | |
| Q4 2020 | -2.6% | +2.0% | -32.8% | |
| Q3 2020 | +8.0% | +2.1% | +14.9% | |
| Q2 2020 | -3.8% | +2.8% | +0.2% | |
| Q1 2020 | -6.7% | -0.2% | +9.9% | |
| Q4 2019 | -5.6% | -10.7% | -15.4% | |
| Q3 2019 | -3.7% | +0.7% | +11.8% | |
| Q2 2019 | +3.5% | +9.7% | -5.4% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro